Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectiveness

Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectiveness - Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma : Safety and effectiveness

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005847

Enrollment

Registered

2011-08-01

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.TACE-refractory or TACE-failure advanced hepatocellular carcinoma 2.patients appropriate to use sorafenib 3.Child-Pugh score:A ECOG PS:0-1 Hemoglobin >8.5 g/dL Neutorophil >1500 /micro L Platelet >75000 /micro L total bilirubin <2 mg/dL AST, ALT <5 times the upper limit of the normal range in local laboratories

Exclusion criteria

Exclusion criteria: 1.Patients unsuitable for Sorafenib Allergic reaction to Sorafenib, Pregnant women, Poor renal function(required hemodialysis), Past history of thromboembolism or ischemic heart disease Poor control of hypertension 2.Severe vascular invasion(Vp3,4)

Design outcomes

Primary

Measure	Time frame
progression free survival	—

Secondary

Measure	Time frame
time to progression, time to treatment failure, overall survival, response rate, disease control rate, safety	—

Countries

Japan

Contacts

Public ContactKohta Iguchi

Kyoto university hospital surgery

iguchik@kuhp.kyoto-u.ac.jp075-751-3242

Outcome results